Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CAMP4 Therapeutics Corporation - Common Stock (NQ:CAMP)

6.400 -0.350 (-5.19%)
Streaming Delayed Price Updated: 11:22 AM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 59,542
Open 6.580
Bid (Size) 6.380 (100)
Ask (Size) 6.650 (100)
Prev. Close 6.750
Today's Range 6.400 - 6.760
52wk Range 1.305 - 7.790
Shares Outstanding 20,161,073
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗
Here's why a fast-rising pharmaceutical trimmed—and not abandoned—by a specialist fund signals ongoing conviction in the stock. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+29.8%
+29.8%
1 Month
+60.4%
+60.4%
3 Month
+141.5%
+141.5%
6 Month
+341.4%
+341.4%
1 Year
+0.6%
+0.6%

More News

Read More
News headline image
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗
Via The Motley Fool
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
3 Healthcare Companies Insiders Are Buying ↗
Via MarketBeat
Topics Initial Public Offering
News headline image
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
Wednesday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
Camp4 Reports Q2 Revenue Beats Estimates ↗
Via The Motley Fool
News headline image
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Sequans Appoints Jason W. Cohenour to Board of Directors
Via Newsfile
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
This Sandisk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
Via Benzinga
News headline image
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Why ThredUp Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
From CAMP4 Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is CAMP4 Therapeutics Corporation - Common Stock publicly traded?
Yes, CAMP4 Therapeutics Corporation - Common Stock is publicly traded.
What exchange does CAMP4 Therapeutics Corporation - Common Stock trade on?
CAMP4 Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for CAMP4 Therapeutics Corporation - Common Stock?
The ticker symbol for CAMP4 Therapeutics Corporation - Common Stock is CAMP on the Nasdaq Stock Market
What is the current price of CAMP4 Therapeutics Corporation - Common Stock?
The current price of CAMP4 Therapeutics Corporation - Common Stock is 6.400
When was CAMP4 Therapeutics Corporation - Common Stock last traded?
The last trade of CAMP4 Therapeutics Corporation - Common Stock was at 12/16/25 11:22 AM ET
What is the market capitalization of CAMP4 Therapeutics Corporation - Common Stock?
The market capitalization of CAMP4 Therapeutics Corporation - Common Stock is 129.03M
How many shares of CAMP4 Therapeutics Corporation - Common Stock are outstanding?
CAMP4 Therapeutics Corporation - Common Stock has 129M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.